Teva Pharmaceutical Industries (NYSE:TEVA) Upgraded by Argus to “Buy”

Argus upgraded shares of Teva Pharmaceutical Industries (NYSE:TEVA – Free Report) from a hold rating to a buy rating in a research report report published on Wednesday, MarketBeat.com reports. Argus currently has $20.00 price target on the stock. A number of other brokerages have also recently weighed in on TEVA. Bank of America lifted their […]

Leave a Reply

Your email address will not be published.

Previous post Keefe, Bruyette & Woods Cuts Granite Point Mortgage Trust (NYSE:GPMT) Price Target to $3.25
Next post LiveRamp (NYSE:RAMP) Receives Buy Rating from Benchmark